ストックスクリーナーアプリを入手
397.27
0.16%
0.63
アフターアワーズ：
394.85
-2.42
-0.61%
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein - Yahoo Finance
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally - The Motley Fool
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock - MSN
Vertex Pharmaceuticals (VRTX) Gains FDA Approval for ALYFTREK™ - GuruFocus.com
Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment - Reuters.com
Vertex Pharmaceuticals (VRTX) Stock Surges Amid Mixed Analyst Ra - GuruFocus.com
Vertex Pharmaceuticals announces FDA approval for ALYFTREK By Investing.com - Investing.com UK
Vertex Pharma (VRTX) Announces US FDA Approval of ALYFTREK, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - StreetInsider.com
Vertex Secures FDA Approval for Groundbreaking Once-Daily Cystic Fibrosis Treatment ALYFTREK - StockTitan
Vertex's TRIKAFTA Wins Major FDA Expansion for Cystic Fibrosis Treatment in Young Children - StockTitan
Barclays Has Lowered Expectations for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price - MarketBeat
BMO Capital Markets Lowers Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $520.00 - MarketBeat
HC Wainwright Has Lowered Expectations for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price - MarketBeat
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? - Yahoo! Voices
Is Vertex Stock A Sell After Non-Opioid Pain Drug Whiffs It? - Investor's Business Daily
Principal Financial Group Inc. Buys 21,649 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Oppenheimer Downgrades Vertex Pharmaceuticals (VRTX) After Study Results - GuruFocus.com
Vertex Plummets With Pain Drug No Better Than Placebo in Study - MSN
Cystic Fibrosis Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, and Key Companies involved by DelveInsight | Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharma - Barchart
Vertex’s Suzetrigine Disappoints In Phase II Pain Study, But Phase III Planning Under Way - Citeline News & Insights
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Vertex Dives 11% On A 'Worst-Case Scenario' For Its Non-Opioid Pain Drug - Yahoo! Voices
Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX): ‘I Think You Should Buy The Dip Here’ - Insider Monkey
Vertex Pharmaceuticals (NASDAQ:VRTX) Lowered to "Market Perform" Rating by Oppenheimer - MarketBeat
Stocks on the Move: Vertex Pharma, Shake Shack, Zoom, Lennar and Home Depot - MSN
Oppenheimer downgrades Vertex after lumbosacral radiculopathy study - TipRanks
Bank of America Issues Pessimistic Forecast for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price - MarketBeat
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data? - Yahoo Finance
Vertex’s stock hurt after non-opioid pain drug shows benefit similar to placebo - Yahoo Finance
Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint - BioPharma Dive
Vertex's non-opioid pain drug no better than placebo in sciatica study - FirstWord Pharma
Accenture, Robinhood and Coinbase, Vertex: Market Minute - Yahoo Finance
Vertex Pharmaceuticals is Now Oversold (VRTX) - Nasdaq
Vertex stock plummets as study results show non-opioid pain drug no better than placebo - The Boston Globe
Vertex Pharmaceuticals Stock Heads for Worst Day in 4 Years - Schaeffers Research
Vertex's $10 Billion Blow: Painkiller Trial Results Spark Invest - GuruFocus.com
Vertex Pharmaceuticals (NASDAQ:VRTX) Hits New 52-Week LowWhat's Next? - MarketBeat
Vertex Pharmaceuticals Inc. (VRTX) Investigated For - GlobeNewswire
Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securities Fraud; Block & Leviton ... - The Bakersfield Californian
Vertex Pain Drug Doesn’t Beat Placebo. The Company Says It Still Sees Promise. - Barron's
Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results - MSN
Vertex's $10 Billion Blow: Painkiller Trial Results Spark Investor Panic - Yahoo Finance
Vertex's painkiller results match placebo in study, shares tumble - Reuters.com
Vertex Phase II suzetrigine study disappoints - The Pharma Letter
Vertex Dips on Mixed Phase II Data for Non-Opioid Pain Therapy - BioSpace
Vertex stock touches 52-week low at $389.73 amid market shifts - Investing.com UK
Here’s Why Vertex Pharmaceuticals Incorporated (VRTX) Slid in Q3 - Yahoo Finance
Vertex’s non-opioid painkiller meets trial goal — but investors aren’t sold - The Business Journals
Vertex Pharma’s suzetrigine meets Phase 2 primary endpoint in radiculopathy - TipRanks
Vertex's pain trial hits endpoint but sinks stock as placebo comparison spooks investors - Fierce Biotech
Vertex shares tumble following Phase 2 pain study results By Investing.com - Investing.com Canada
Vertex touts pain drug results, but medicine does not outperform placebo in sciatica study - STAT
Vertex Pharmaceuticals Shares Drop on Mixed Results in Drug Trial - MarketWatch
Vertex’s non-opioid drug succeeds in back pain trial (NASDAQ:VRTX) - Seeking Alpha
0.90%
2.75%
大文字化:
|
ボリューム (24 時間):